[go: up one dir, main page]

PE68199A1 - PHARMACEUTICAL COMPOSITION OF GASTRIC RESIDENCE - Google Patents

PHARMACEUTICAL COMPOSITION OF GASTRIC RESIDENCE

Info

Publication number
PE68199A1
PE68199A1 PE1998000281A PE00028198A PE68199A1 PE 68199 A1 PE68199 A1 PE 68199A1 PE 1998000281 A PE1998000281 A PE 1998000281A PE 00028198 A PE00028198 A PE 00028198A PE 68199 A1 PE68199 A1 PE 68199A1
Authority
PE
Peru
Prior art keywords
acid
pharmaceutical composition
salts
gastric residence
generating system
Prior art date
Application number
PE1998000281A
Other languages
Spanish (es)
Inventor
Besse Jergme
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo filed Critical Synthelabo
Publication of PE68199A1 publication Critical patent/PE68199A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)

Abstract

CARACTERIZADA PORQUE COMPRENDE a)UN PRINCIPIO ACTIVO QUE CONSISTE DE UNA BENZAMIDA O SU SAL, PARTICULARMENTE ES EL CLORHIDRATO DE TIAPRIDE, AMISULPRIDA, SULPIRIDA, O SUS SALES, O SUS ENANTIOMEROS; b)UN SISTEMA GENERADOR DE CO2, COMPRENDE AL MENOS UN AGENTE GENERADOR DE CO2 Y AL MENOS UN COMPUESTO ACIDO ELEGIDO ENTRE ACIDO MONO Y POLICARBOXILICOS; DE PREFERENCIA ES EL ACIDO TARTARICO, SUCCINICO, CITRICO O SUS SALES; c)UN MEDIO QUE PERMITE LA RETENCION PARCIAL DE CO2 GENERADO POR DICHO SISTEMA GENERADOR DE CO2, QUE CONSISTE AL MENOS DE UN POLIMERO HIDROFILICO EL CUAL ES UN DERIVADO CELULOSICO, EN PARTICULAR HIDROXIPROPILCELULOSA, HIDROXIPROPILMETILCELULOSA. TAMBIEN SE CARACTERIZA PORQUE SE PRESENTA EN FORMA DE UN COMPRIMIDO FLOTANTE. LA COMPOSICION MEJORA LA BIODISPONIBILIDAD DE LAS BENZAMIDAS POR VIA ORALCHARACTERIZED BECAUSE IT INCLUDES a) AN ACTIVE PRINCIPLE THAT CONSISTS OF A BENZAMIDE OR ITS SALT, PARTICULARLY IS THE CHLORHYDRATE OF TIAPRIDE, AMISULPRIDE, SULPIRIDE, OR ITS SALTS, OR THEIR ENANTIOMERS; b) A CO2 GENERATING SYSTEM, INCLUDING AT LEAST ONE CO2 GENERATING AGENT AND AT LEAST ONE ACID COMPOSITE CHOSEN BETWEEN MONO ACID AND POLYCARBOXYLIC ACIDS; OF PREFERENCE IS THE ACID TARTARICO, SUCCINICO, CITRICO OR ITS SALTS; c) A MEANS THAT ALLOWS THE PARTIAL RETENTION OF CO2 GENERATED BY SUCH A CO2 GENERATING SYSTEM, WHICH CONSISTS OF AT LEAST ONE HYDROPHILIC POLYMER, WHICH IS A CELLULOSIC DERIVATIVE, IN PARTICULAR HYDROXYPROPYLcellulose. IT IS ALSO CHARACTERIZED BECAUSE IT IS PRESENTED IN THE FORM OF A FLOATING TABLET. THE COMPOSITION IMPROVES THE BIOAVAILABILITY OF BENZAMIDES BY ORAL USE

PE1998000281A 1997-04-18 1998-04-17 PHARMACEUTICAL COMPOSITION OF GASTRIC RESIDENCE PE68199A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9704803A FR2762213B1 (en) 1997-04-18 1997-04-18 PHARMACEUTICAL COMPOSITION WITH GASTRIC RETENTION

Publications (1)

Publication Number Publication Date
PE68199A1 true PE68199A1 (en) 1999-07-15

Family

ID=9506077

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000281A PE68199A1 (en) 1997-04-18 1998-04-17 PHARMACEUTICAL COMPOSITION OF GASTRIC RESIDENCE

Country Status (19)

Country Link
EP (1) EP0983065A1 (en)
JP (1) JP2001523241A (en)
KR (1) KR20010006353A (en)
CN (1) CN1252720A (en)
AR (1) AR015586A1 (en)
AU (1) AU737634B2 (en)
CA (1) CA2286081A1 (en)
FR (1) FR2762213B1 (en)
HU (1) HUP0002455A3 (en)
IL (1) IL131995A0 (en)
JO (1) JO2017B1 (en)
MA (1) MA26482A1 (en)
NO (1) NO995039L (en)
NZ (1) NZ500288A (en)
PE (1) PE68199A1 (en)
PL (1) PL336273A1 (en)
TN (1) TNSN98049A1 (en)
WO (1) WO1998047506A1 (en)
ZA (1) ZA983258B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
FR2784583B1 (en) * 1998-10-16 2002-01-25 Synthelabo PHARMACEUTICAL COMPOSITION WITH GASTRIC RESIDENCE AND CONTROLLED RELEASE
FR2790388B1 (en) * 1999-03-04 2001-04-13 Synthelabo PHARMACEUTICAL COMPOSITIONS COMPRISING A BENZAMIDE AND AT LEAST ONE ABSORPTION PROMOTER
EP1245227A1 (en) 2001-03-31 2002-10-02 Jagotec Ag A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same
FR2949061B1 (en) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma FLOATING MICROGRANULES
DK2719376T3 (en) 2012-10-12 2015-06-15 Omya Int Ag Gastroretentiv drug formulation and delivery systems and their method of preparation by the use of functional calcium carbonate
KR20200110317A (en) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 Crystal form and method for preparing the same
CN118593482A (en) 2017-12-05 2024-09-06 赛诺维信制药公司 Non-racemic mixture and its use
JP7044649B2 (en) * 2018-06-28 2022-03-30 株式会社ファンケル Intragastric floating tablets
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2020247603A1 (en) * 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2023214018A1 (en) 2022-05-06 2023-11-09 Galenix Innovations Gastro-retentive swellable sustained release composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (en) * 1978-01-20 1979-08-17 Ile De France NEW DERIVATIVES OF 4-AMINO-5-ALKYLSULFONYL ORTHO-ANISAMIDES, THEIR METHODS OF PREPARATION AND THEIR APPLICATION AS PSYCHOTROPES
FR2554718B1 (en) * 1983-11-14 1986-04-04 Ethypharm Sa NEW ORAL SULPIRIDE FORMS FOR SULPIRIDE
FR2556964A1 (en) * 1983-12-23 1985-06-28 Ile De France NEW GALENIC FORMS OF SULPIRIDE USED ORALALLY
JPS62178518A (en) * 1986-01-30 1987-08-05 Toho Yakuhin Kogyo Kk New long-acting sulpiride tablets
JPH0776172B2 (en) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 Matrice locks
CA2039742A1 (en) * 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials

Also Published As

Publication number Publication date
WO1998047506A1 (en) 1998-10-29
JP2001523241A (en) 2001-11-20
PL336273A1 (en) 2000-06-19
NO995039L (en) 1999-12-17
NZ500288A (en) 2001-03-30
TNSN98049A1 (en) 2005-03-15
EP0983065A1 (en) 2000-03-08
HUP0002455A3 (en) 2001-01-29
FR2762213A1 (en) 1998-10-23
CN1252720A (en) 2000-05-10
MA26482A1 (en) 2004-12-20
ZA983258B (en) 1998-10-19
CA2286081A1 (en) 1998-10-29
FR2762213B1 (en) 1999-05-14
AU7341698A (en) 1998-11-13
AU737634B2 (en) 2001-08-23
HUP0002455A2 (en) 2000-12-28
JO2017B1 (en) 1999-05-15
NO995039D0 (en) 1999-10-15
AR015586A1 (en) 2001-05-16
IL131995A0 (en) 2001-03-19
KR20010006353A (en) 2001-01-26

Similar Documents

Publication Publication Date Title
TR199500826A2 (en) Multiple unit tablet dosage form 2.
PE68199A1 (en) PHARMACEUTICAL COMPOSITION OF GASTRIC RESIDENCE
CY1107675T1 (en) TRAMADOLIS MEDICINES
ES2195344T3 (en) PHARMACEUTICAL COMPOSITION PRESENTING AN IMPROVED ANTITUMORAL ACTIVITY AND / OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMORAL AGENT AND A HYDROXYMIC ACID DERIVATIVE.
ES2172239T3 (en) OSMOTIC SYSTEM OF LIBERATION OF PHARMACOS.
MX9207263A (en) SYSTEM FOR THE SUPPLY OF AN ACTIVE SUBSTANCE FOR SUSTAINED LIBERATION.
DK1390378T3 (en) Pharmaceutically active uridine esters
ES2172303T3 (en) THERAPEUTIC AGENTS OBTAINED BY ENZYMATIC CATALYSIS.
ES2176106B1 (en) TRIMETAZIDINE PROLONGED MARRIAGE RELEASE COMPRESSED AFTER ORAL ADMINISTRATION.
CA2273420A1 (en) Matrix tablet permitting sustained release of gliclazide after oral administration
NO981944D0 (en) Lipopolyamines as transfection agents as well as their pharmaceutical use
MX170909B (en) PROCEDURE TO PREPARE AN AGENT FOR THE DETECTION AND DETERMINATION OF PEROXIDASE ACTIVITY, RESULTING PRODUCT AND ITS EMPLOYMENT
UY26371A1 (en) IMIDAZO-3-IL-AMINAS BICICLICAS, PROCEDURE FOR ITS PREPARATION AND MEDICINES THAT CONTAIN THEM
IT1314185B1 (en) PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION OF SUBSTANCES ACTIVELY SOLUBLE IN AQUEOUS MEDIA
ES2174293T3 (en) PHARMACEUTICAL MICROSPHERES OF VALPROIC ACID FOR ORAL ADMINISTRATION.
ES2159362T3 (en) USE OF 1- (2-NAFT-2-ILETIL) -4- (3-TRIFLUOROMETILFENIL) -1,2,3,6-TETRAHYDROPIRIDINE FOR THE PREPARATION OF MEDICINES INTENDED FOR THE TREATMENT OF AMIOTROPHIC SIDE SCLEROSIS.
DK0625355T3 (en) Tablet with improved bioavailability containing dichloromethylene phosphonic acid as active substance
TR199801082T2 (en) New phospholipid derivatives of phosphonocarbicylic acids, their production, as well as their use as antiviral pharmaceuticals.
ATE253940T1 (en) STABLE SOLUTION OF CALCITRIOL FOR PACKAGING IN VIALS
DK72289A (en) CEPHEMCARBOXYLIC ACID ESTERS, THEIR PREPARATION AND USE
AR056268A1 (en) TABLETS THAT INCLUDE A BIOLOGICALLY ACTIVE SUBSTANCE AND A EXCIPIENT
AR004503A1 (en) USE OF L-CARNITINE, L-ACRYLIC L-CARNITINES IN WHICH THE ACIL, LINEAR OR BRANCHED GRUO, HAS BETWEEN 2 AND 6 CARBON ATOMS AND THEIR ACCEPTABLE SALES, AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH COMPOUNDS
CY1105545T1 (en) STATIN THERAPY TO ENHANCE THE PRESERVATION OF MENTAL FUNCTION
PE20020055A1 (en) STABLE LIQUID AND SOLID FORMULATIONS INCLUDING A NON-SEDATING ANTIHISTAMINE AND A NASAL DECONGESTANT
AR031846A1 (en) COMBINATION OF ACTIVE SUBSTANCES, MEDICATIONS AND FORMULATIONS THAT CONTAIN IT, AND USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PAIN

Legal Events

Date Code Title Description
FA Abandonment or withdrawal